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OBJECTIVE: The prescription of prostate non-selective
alpha-1 antagonists (terazosin, doxazosin, prazosin) may
require extra health care visits for dose titration and for
monitoring treatment safety and effectiveness. From a
retrospective cohort study using pension related fee-for-
service supplementary Medigap health claims data, we
estimated the impact of alpha-1 antagonist initiation on
health care use and costs for men with BPH. METHODS:
Claims data from a two year period included medical and
prescription drug information for 53,824 men with BPH.
We compared men who initiated alpha-1 antagonists
with a random sample of nonusers. Inpatient and outpa-
tient costs were calculated as the sum of the Medicare
paid amount, the Medigap co-pay amount, and the Medi-
gap deductible amount. Comparisons used generalized esti-
mating equation (GEE) or Poisson regression methods to
estimate the change from four months pre- to four months
post-initiation and an imputed date for non-users. This pe-
riod coincided with the recommended time for treatment ti-
tration and a period of increased hypotensive event risk in
this population. RESULTS: Adjusting for baseline health
care use, age, and co-morbidity, alpha-1 antagonist initia-
tors had a mean of 4.2 more physician visits post-initiation
than men who did not initiate among those who did not
use other antihypertensives and 5.8 more visits among men
who did use antihypertensives (p  0.05). The correspond-
ing adjusted difference in cost of physician visits was $176
per man for those who did not use other antihypertensives
and $267 for those who did use other antihypertensives (p
 0.05). Initiation was also significantly associated with an
increase of 0.15 hospital stays per 1,000 person-days
among non-users of other antihypertensives and an in-
crease of 0.24 hospital stays per 1,000 person-days among
users of other antihypertensives. CONCLUSION: The in-
creased number of physician visits, hospital stays, and phy-
sician visit costs post-initiation should be considered in
cost-effectiveness analyses of BPH treatments.
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OBJECTIVES: To compare the cost-effectiveness of in-
travaginal prostaglandin E2 gel and intravaginal miso-
prostol tablets for preinduction cervical ripening. METH-
ODS: This study was a modeled cost-effectiveness analysis
from the hospital perspective. A decision analysis was
used to estimated costs and percentage of women achiev-
ing vaginal delivery with either intravaginal prostaglan-
din E2 or intravaginal misoprostol. Costs were assessed
in 1999 dollars and obtained from Brigham and Women’s
Hospital in Boston, Massachusetts. Probabilities and per-
centage of patients achieving vaginal delivery within 24
hours were obtained by meta-analysis of published trails.
Health resoursed used for the rate of delivery after each
dose of the study agents were obtained through an expert
physician pane. RESULTS: The primary outcome mea-
sures were direct medical costs, in 1999 dollars, and ef-
fect was measured as percentage of patients achieving
successful cervical ripening, leading to labor induction
and vaginal delivery before use of an alternative method.
The meta-analysis included a total of 9 trials incorporat-
ing 1,056 patients. Direct medical costs for prostaglandin
E2 was $1,852.14 and $1,941.51 for misoprostol. Eighty-
five percent of patients receiving misoprostol and 71% of
patients receiving prostaglandin E2 achieved vaginal de-
livery before the use of an alternative method. CON-
CLUSION: Though misoprostol is less expensive per
dose compared to prostaglandin E2, the overall treatment
costs are higher when encompassing costs associated with
adverse effects. Therefore, an incremental cost analysis
demonstrates that if the hospital is willing to pay $638
more per patient, there will be a 1% greater chance of
achieving vaginal delivery.
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OBJECTIVES: The risk of post-operative nausea and
vomiting (PONV) following gynecological surgery re-
mains high despite effective prophylactic medications.
Thus, the objectives of this study were to determine if
standardized orders for the prophylaxis and treatment of
PONV in gynecological surgery patients: 1) reduce
PONV occurrence; 2) reduce total costs; and 3) influence
the choice of medications used for PONV prophylaxis
and treatment. METHODS: A retrospective design was
employed in which a random sample of 200 patients was
selected from each of the two 6 month phases before
(pre) and after (post) the implementation of standardized
orders for PONV prophylaxis and treatment. The pri-
mary outcome was the occurrence of any PONV episode.
Logistic regression was used to adjust for potential con-
founding factors. RESULTS: Characteristics were similar
except for surgical and anesthesia length between phases.
The proportion of patients receiving PONV prophylaxis
increased from 31% (pre) to 47% (post, p  0.002).
